Cocrystal Pharma's First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026

Core Insights - Cocrystal Pharma, Inc. is advancing its oral protease inhibitor CDI-988 for norovirus treatment and prevention, with initial study results to be presented at ICAR2026 [1][2][3] Company Overview - Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on developing antiviral therapeutics targeting various viruses, including noroviruses and coronaviruses [6] Product Development - CDI-988 is the first oral antiviral drug candidate aimed at preventing and treating acute norovirus gastroenteritis, developed using a proprietary structure-based drug discovery platform [2][3] - The ongoing Phase 1b challenge study at Emory University School of Medicine evaluates CDI-988 as both a prophylactic and therapeutic option for norovirus infection [2][3] Industry Context - Norovirus is a highly contagious virus causing acute gastroenteritis, leading to approximately 200,000 deaths globally each year and an estimated societal cost of $60 billion [5] - In the U.S., norovirus accounts for about 21 million cases of acute gastroenteritis annually, resulting in significant hospitalizations and economic burden [5]